Retatrutide

Retatrutide (GLP-1/GIP/GCGR Triple Receptor Agonist)

Evidence & Status

  • Strong Human Evidence
  • Strong

At a Glance

An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Published Phase II trials reported findings in obesity and type 2 diabetes; Phase III TRIUMPH-1 is completed and TRIUMPH-Outcomes is active not recruiting, without posted results identified in this audit.

Plain English

Researchers study Retatrutide because it simultaneously activates three hormone pathways involved in metabolic regulation — GLP-1, GIP, and glucagon receptors. Published Phase II trials investigated obesity and type 2 diabetes. Its Phase III program includes completed TRIUMPH-1 and active-not-recruiting TRIUMPH-Outcomes; the registry status of those studies does not by itself establish treatment efficacy. Retatrutide remains investigational and is not FDA-approved.

Overview

Retatrutide (LY3437943) is an investigational triple agonist of the GIP, GLP-1, and glucagon receptors. Verified human evidence in this record consists of controlled Phase II obesity and type 2 diabetes studies. It remains investigational and is not FDA-approved; trial findings and any future Phase III results must remain tied to their specific population, protocol, and primary source.

Research Summary

Retatrutide has published controlled human Phase II evidence in obesity and type 2 diabetes while it remains investigational. Phase III TRIUMPH-1 (NCT05929066) is completed; TRIUMPH-Outcomes (NCT06383390) is active not recruiting, with no posted results identified in this audit. Registry records support trial status and design only, not efficacy conclusions. No FDA-approved indication or approved dosing exists.

Research Areas

  • Investigational obesity research
  • Investigational type 2 diabetes research

Safety & Risks

Serious Risks

  • Long-term human safety and clinical outcomes remain incompletely characterized; not approved for use outside clinical trials

Reported Side Effects

  • Nausea
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • Constipation
  • Injection site reactions
  • Elevated heart rate (dose-dependent)
  • Decreased lean mass at highest doses
United States
Investigational; Phase III TRIUMPH-1 (NCT05929066) is completed and TRIUMPH-Outcomes (NCT06383390) is active not recruiting; no FDA-approved form
United Kingdom
Current authorization status not established in this record
Australia
Current authorization status not established in this record
Canada
Current authorization status not established in this record

Citations & Sources